Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations – A Cause for Concern

• References

• 1 Bertina RM, Rosendaal FR, Koeleman BPC, Koster T, Driven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 2 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 3 Mannucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001; 98: 21-2.
• 4 Green D. Genetic hypercoagulability: screening should be an informed choice. Blood 2001; 98: 20.
• 5 Preston FE, Kitchen S, Jennings I, Woods TAL. A UK National External Quality Assessment Scheme (UK Neqas) for molecular genetic testing for the diagnosis of familial thrombophilia. Thromb Haemost 1999; 82: 1556-7.